Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants-Reference-Cited by-同舟云学术

Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants

Published:2019-05-26 Issue:7 Volume:17 Page:1064-1072
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Testa Sophie¹,Legnani Cristina²,Antonucci Emilia²,Paoletti Oriana¹,Dellanoce Claudia¹,Cosmi Benilde³,Pengo Vittorio⁴,Poli Daniela⁵,Morandini Rossella¹,Testa Roberto⁶,Tripodi Armando⁷,Palareti Gualtiero²,

Affiliation:

1. Haemostasis and Thrombosis Center Ospedale di Cremona Cremona Italy

2. Arianna Anticoagulazione Foundation Bologna Italy

3. Angiology and Blood Coagulation University Hospital of Bologna Bologna Italy

4. Department of Cardiac, Thoracic and Vascular Sciences Cardiology Clinic Thrombosis Centre University of Padua Padova Italy

5. Thrombosis Centre AOU Careggi Firenze Italy

6. Clinical Laboratory and Molecular Diagnosis INRCA‐IRCCS National Institute Ancona Italy

7. Angelo Bianchi Bonomi Hemophilia and Thrombosis Center IRCCS CàGranda Maggiore Hospital Foundation Milano Italy

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jth.14457

Reference28 articles.

1. Oral Anticoagulant Therapy

2. (FDA) FaDA.Pradaxa ‐ clinical pharmacology and biopharmaceutics review(s).2010.https://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022512Orig1s000ClinPharmR_Corrrected%203.11.2011.pdf(accessed 17 January 2019).https://wwwaccessdatafdagov/drugsatfda_docs/nda/2010/022512Orig1s000ClinPharmR_Corrrected%203112011pdf. 2010.

3. (FDA) FaDA.Xarelto ‐ clinical biopharmaceutics review(s).2011.http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022406Orig1s000ClinPharmR.pdf(accessed 26 September 2017). 2011.

4. (FDA) FaDA.Eliquis ‐ clinical pharmacology and biopharmaceutics review(s).2012.http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202155Orig1s000ClinPharmR.pdfAccessed 26 September 2017.

5. (EMA) EMA.Pradaxa ‐ summary of product characteristics.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf. Accessed 26 September 2017.

Cited by 85 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of reduced DOAC doses in atrial fibrillation patients does not always lead to good anticoagulation levels and avoid adverse events;International Journal of Cardiology;2024-12

2. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS);European Heart Journal;2024-08-30

3. Strategies of anticoagulant therapy in various clinical variants of antiphospholipid syndrome;The Clinician;2024-06-24

4. Impact of renal function variability on long-term prognosis in ischemic stroke patients with atrial fibrillation;Frontiers in Neurology;2024-04-22

5. Thrombotic events associated with low baseline direct oral anticoagulant levels in atrial fibrillation: the MAS study;Blood Advances;2024-04-10